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ABSTRACT
Introduction Pharmaceutical treatment options for 
patients with type 2 diabetes mellitus (T2DM) have 
increased to include multiple classes of oral glucose- 
lowering agents but without accompanying guidance 
on which of these may most benefit individual patients. 
Clinicians lack information for treatment intensification 
after first- line metformin therapy. Stratifying patients 
by simple clinical characteristics may improve care by 
targeting treatment options to those in whom they are 
most effective. This academically designed and run three- 
way crossover trial aims to test a stratification approach 
using three standard oral glucose- lowering agents.
Methods and analysis TriMaster is a randomised, 
double- blind, crossover trial taking place at up to 25 
clinical sites across England, Scotland and Wales. 520 
patients with T2DM treated with either metformin alone, 
or metformin and a sulfonylurea who have glycated 
haemoglobin (HbA1c) >58 mmol/mol will be randomised 
to receive 16 weeks each of a dipeptidyl peptidase‐4 
inhibitor, sodium- glucose co- transporter-2 inhibitor and 
thiazolidinedione in random order. Participants will be 
assessed at the end of each treatment period, providing 
clinical and biochemical data, and their experience of 
side effects. Participant preference will be assessed on 
completion of all three treatments. The primary endpoint 
is HbA1c after 4 months of therapy (allowing a range of 
12–18 weeks for analysis). Secondary endpoints include 
participant- reported preference between the three 
treatments, tolerability and prevalence of side effects.
Ethical approval This study was approved by National 
Health Service Health Research Authority Research Ethics 
Committee South Central—Oxford A, study 16/SC/0147. 
Written informed consent will be obtained from all 
participants. Results will be submitted to a peer- reviewed 
journal and presented at relevant scientific meetings. 
A lay summary of results will be made available to all 
participants.
Trial registration numbers 12039221; 2015-002790-38 
and NCT02653209.
BACKGROUND AND RATIONALE
In recent years the choice of therapies 
designed to lower glucose in patients with 
type 2 diabetes (T2DM) has increased1 but 
Strengths and limitations of this study
 ► This is the first blinded three- way crossover trial 
of glucose- lowering therapies in type 2 diabetes, 
allowing comparison of short- term treatment re-
sponse and side effects across three agents within 
the same individuals.
 ► This study design enables assessment of stratifica-
tion allowing for within- person variation in response.
 ► This will be the first study to assess patient prefer-
ence for choosing between three glucose- lowering 
therapies.
 ► A limitation is that only short- term glycaemic re-
sponse and side effects can be assessed in a study 
of this design.
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there remains limited information as to which patients 
may respond well, moderately or poorly to any of the 
treatment options.2 3 Treatment intensification is recom-
mended in a stepwise approach, with guidelines usually 
including a number of different agents after metformin 
in those without established cardiac or renal disease.2 4
T2DM is a heterogenous condition and response 
to glucose- lowering therapy appears to vary substan-
tially between individuals. Therefore, identification of 
subgroups of patients who respond well or poorly to 
a specific therapy, or with an altered risk of treatment- 
specific side effects, could improve targetting of 
treatment. This stratified approach to therapy is most 
likely to be successful if based on clinical characteristics 
and biomarkers that are readily available in routine clin-
ical care: T2DM is common, most therapies are relatively 
inexpensive and most management is undertaken in 
primary care, therefore stratification based on expensive 
biomakers, or those with limited availability, is unlikely to 
be widely adopted.
A number of previous studies have shown simple clinical 
characteristics and biomarkers are associated with variation 
in glycaemic response for individual therapies.5–8 However, 
to be most useful for stratification a marker needs to predict 
Consented and assessed for eligibility
(screened) 
Randomised to allocation order
(ABC, ACB, BAC, BCA, CAB, CBA)
Allocated to first intervention (A or B or C)
• Received allocated intervention 
• Did not receive allocated intervention
Excluded 
• Not meeting inclusion criteria 
• Declined to participate 
• Other reasons
Follow-Up
Analysed 
Excluded from analysis  
- Ineligible 
- Other reasons
Analysis
Baseline visit 
Allocation Crossover
Randomised in error
• Ineligible 
• Other reasons
Enrolment
TriMaster CONSORT Flow Diagram 
Allocated to second intervention (A or B or C)
• Received allocated intervention 
• Did not receive allocated intervention 
Allocated to third intervention (A or B or C) 
• Received allocated intervention 
• Did not receive allocated intervention 
Completed study as planned 
Completed study, not as planned 
Did not complete study 
• Lost to follow-up 
• Withdrew 
Identified and/or referred
Did not complete first intervention >12 
weeks 
• Withdrew from trial 
• <12 weeks of intervention
Did not complete second intervention 
>12 weeks 
• Withdrew from trial 
• <12 weeks of intervention 
Did not complete third intervention >12 
weeks 
• Withdrew from trial 
• <12 weeks of intervention 
Withdrew before/at baseline visit
Database lock
Figure 1 TriMaster consort diagram.
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differential response between therapies.9 Work by the 
MASTERMIND consortium using routine and trial data has 
strengthened the evidence that clinical features are asso-
ciated with differential glycaemic response to dipeptidyl 
peptidase‐4 (DPP4)- inhibitors, sodium- glucose co- trans-
porter-2 (SGLT2)- inhibitors and thiazolidinediones.10–12 
Analysis of data from the UK Clinical Practice Research 
Datalink (CPRD) and a Diabetes Outcome Progression 
Trial (ADOPT) trial showed that sex and body mass index 
(BMI) above and below 30 were associated with differen-
tial glycaemia response between sulfonylureas and thiazo-
lidinediones.10 In addition, individuals within a normal 
estimated glomerular filtration rate (eGFR) range, with a 
higher eGFR show a better glycaemia response to SGLT2 
inhibitors while individuals with a lower eGFR may have a 
better glycaemic response when taking a DPP4 inhibitor 
(Janssen, personal communication from MASTERMIND 
industry group, 2014). The features identified (sex, obesity 
and renal function), are routinely measured at low cost, 
meaning potential stratification using these characteristics 
could be easily implemented in clinical practice.
TriMaster aims to test potential glycaemic therapy 
stratification in T2DM using response to three stan-
dard glucose- lowering agents. It will determine whether 
subgroups defined by routinely measured features 
respond to a greater or lesser degree (with regard to 
glycaemic change) to DPP4 inhibitors, SGLT2 inhibi-
tors and thiazolidinediones, and provide a resource for 
further investigation of stratification between these ther-
apies in the future.
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
 ► Clinical diagnosis of T2DM.
 ► Age ≥30 and ≤80 years.
 ► Currently treated with one or two classes of oral 
glucose- lowering therapy (given either as separate or 
combined medications), that do not include a DPP4 
inhibitor, a SGLT2 inhibitor or a thiazolidinedione.
 ► Diabetes duration ≥12 months.
 ► No change in diabetes treatment (new treatments or 
dose change) within previous 3 months.
 ► HbA1c > 58 mmol/mol (>7.5%) and ≤110 mmol/mol 
(≤12.2%).
 ► eGFR ≥60 mL/min/1.73 m².
 ► Able and willing to give informed consent.
 ► Changes in glucose- lowering therapy or dose within last 3 months.
 ► ALT >2.5×upper limit of the assay normal range or known liver disease, 
specifically bilirubin >30 μmol/L that is associated with other evidence of liver 
failure.
 ► Insulin treated within the last 12 months.
 ► Treated with study drugs within the last 3 months.
 ► Limb ischaemia shown by absence of both pulses in one or both feet.
 ► Currently treated with corticosteroids.
 ► Currently treated with rifampicin, gemfibrozil, phenytoin and carbamazepine.
 ► Active infection (any infection requiring antibiotics).
 ► Foot ulcer requiring antibiotics within previous 3 months.
 ► Recent (within 3 months) significant surgery or planned surgery (excluding minor 
procedures).
 ► Acute cardiovascular episode (angina, myocardial infarction, stroke, transient 
ischaemic episode) occurring within the previous 3 months.
 ► History of heart failure.
 ► Current use of loop diuretic therapy (furosemide or bumetanide).
 ► History of bladder carcinoma.
 ► Current/ongoing investigation for macroscopic haematuria.
 ► History of diabetic ketoacidosis.
 ► History of pancreatitis.
 ► Pregnant, breastfeeding or planning a pregnancy over the study period.
 ► Concurrent participation on another Clinical Trial of an Investigational Medicinal 
Product (CTIMP) where the IMP is currently being taken, or without sufficient 
washout period (five times the longest half- life of the study IMPs) and without 
consultation with the CTIMP research team.
 ► Unable or unwilling to give informed consent.
 ► Females of childbearing potential must be willing to use an effective method 
of contraception from the time consent is signed until 7 days after treatment 
discontinuation. A negative pregnancy test is required within 7 days prior to 
treatment initiation and will be required for continuation at each study visit.
ALT, alanine aminotransferase 
; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; SGLT2, sodium- glucose co- transporter-2; 
T2DM, type 2 diabetes mellitus.
Table 2 Differences in response between two drugs and two strata in the crossover trial
Patient group Drug A Drug B Difference
In strata (S) HbA1cSA HbA1cSB HbA1cSA−HbA1cSB
Not in strata (N) HbA1cNA HbA1cNB HbA1cNA−HbA1cNB
The null hypothesis is that the difference in achieved HbA1c for the two drugs will be similar for the two groups of participants (ie, HbA1cSA−
HbA1cSB=HbA1cNA−HbA1cNB).
HbA1c, glycated haemoglobin.
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These therapies were selected on the basis of differen-
tial response seen in pilot studies, and the choice of avail-
able oral third- line therapies at the start of the study.
Hypotheses
The trial is designed with the following hypotheses:
1. Patients with insulin resistance, characterised clinical-
ly by a raised BMI (>30 kg/m2), compared with non- 
obese patients will: (i) respond well to pioglitazone, a 
thiazolidinedione that works as an insulin sensitiser13; 
(ii) respond less well to sitagliptin, a DPP4 inhibitor 
which works through stimulating endogenous insulin 
secretion post- prandially.14
2. Patients with modestly reduced eGFR (60–90 mL/
min/1.73 m2), compared with those with eGFR >90 
mL/min/1.73 m2 will: (i) respond less well to canagli-
flozin, an SGLT2 inhibitor, which works through inhib-
iting the active reabsorption of glucose in the proximal 
tube,15 as the reduced eGFR will reduce the glucose- 
lowering efficacy; (ii) respond well to sitagliptin, a DPP4 
inhibitor that is renally cleared, as the reduced eGFR 
will increase plasma DPP4 inhibitor concentrations.
Figure 2 TriMaster schedule of assessment. 1Where baseline visit takes place more than 2 weeks after screening visit, 
eligibility blood samples must be repeated. 2Optional procedure for participants at sites which have previously agreed to 
sample collection. 3Analysis performed on both visit 1 baseline and visit 1 mixed- meal tolerance test samples. Other analyses 
at visit 1 performed on baseline only. DTSQ, Diabetes Treatment Satisfaction Questionnaire; HbA1c, glycated haemoglobin; IMP, 
investigational medicinal product
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PRIMARY OBJECTIVES
To test two hypotheses of drug response stratification 
based on drug mechanism of action and pharmacoki-
netics to answer the following clinical questions:
1. Do obese patients (BMI>30 kg/m2), compared with 
non- obese patients, achieve a lower glycated haemo-
globin (HbA1c) when assigned to pioglitazone rather 
than sitagliptin?
2. Do patients with an eGFR 60–90 mL/min/1.73 m2 
achieve a lower HbA1c, compared with patients with 
an eGFR >90 mL/min/1.73 m2, when assigned to sita-
gliptin rather than canagliflozin?
SECONDARY OBJECTIVES
The design of the study provides people with T2DM the 
unusual opportunity to try a panel of three available 
glucose- lowering therapies and to express a preference 
based on their experience of each. The study’s secondary 
objectives are to determine:
1. Patient treatment preference within hypothesised stra-
ta and overall.
2. Prevalence of side effects within hypothesised strata 
and for specific drugs, to include: weight gain, hypo-
glycaemia, oedema, genital tract infection and discon-
tinuation of therapy.
3. Predefined test of sex heterogeneity with pilot data 
suggesting women are more likely to show an improved 
response relative to men for pioglitazone.
4. Tolerability of treatments within hypothesised strata 
and overall.
METHODS AND ANALYSIS
We have used the Standard Protocol Items: Recommen-
dations for Interventional Trials reporting guidelines in 
the design of the protocol and preparation of this paper16 
(online supplemental appendix 1).
Overview of trial design
TriMaster is a phase IV, academically designed and 
run, multicentre, randomised, double- blind, 12- month 
crossover trial of a DPP4 inhibitor (sitagliptin), thiazoli-
dinedione (pioglitazone) and SGLT2 inhibitor (canagli-
flozin) as a second- line or third- line therapy in patients 
with T2DM who have suboptimal glycaemic control 
on metformin alone or metformin and sulfonylurea 
(figure 1). The three- way crossover will be undertaken 
as an efficient, faster and more cost- effective approach 
to address both hypotheses, requiring fewer participants 
than performing two 2- way cross over studies.
Five hundred and twenty participants with T2DM 
will be recruited, aged 30–80 years on stable doses of 
Table 3 Protocol amendments
Protocol amendments
SA1 v3 06.07.16 Amendment to randomisation process to allocate individual bottles rather than ‘packs’ of 3 bottles to allow for 
shorter expiry dates, and clarification of safety reporting procedures.
SA4 v4 20.03.17 Amendment to exclusion criteria to allow patients who have previously tried the study drugs to be included, as long 
as this has not been in the previous 3 months. The original criteria were unnecessarily strict and did not reflect real- 
world prescribing habits. The amendment also removed the blanket exclusion for patients in concurrent clinical trials, 
providing sufficient washout period between IMPs.
SA6 v5 01.08.17 Amendment to eligibility criteria to include patients taking metformin- only, or metformin and a sulfonylurea. This was 
adjusted due to the change in guidelines and prescribing trends leading to decline in use of sulfonylureas. At the 
time of study design sulfonylureas were the most commonly prescribed second line therapy in the UK. Subsequent 
decline in their use in favour of DPP4 inhibitors and SGLT2 inhibitors,2 resulted in the inclusion of patients currently 
treated with either metformin and sulfonylureas or metformin only. We will perform a sensitivity analysis to determine 
if the difference in study ‘epoch’ (before/after this amendment) has any impact on the main study outcomes.
Altered exclusion criteria also added ‘limb ischaemia’ due to updated safety information for canagliflozin, and an 
upper limit of HbA1c>110 mmol/mol.
SA9 v6 15.05.18 Amendment to sample size due to over- cautious sample calculations (alpha changed to 0.05), extension to 
recruitment period due to delays in regulatory approvals at study set- up and slow early recruitment, and additional 
secondary analysis included on the advice of the Data Monitoring Committee.
SA10 v7 22.02.19 Amendment to study analysis plan. Following advice from the Trial Steering Committee statistician, the protocol was 
amended to analyse only those completing at least 12 weeks on therapy, as this will determine whether the strata 
result in differences in response (we cannot adequately measure glycaemic response by HbA1c if the patient has been 
on the drug for less than 12 weeks). A separate analysis will be performed to determine whether the strata influence 
tolerability by assessing whether the proportion completing at least 12 weeks on therapy differs by drug and strata.
SA12
v8 20.03.20
Amendment to ensure ongoing participant safety and study integrity during COVID-19 pandemic. Urgent safety 
measures included (i) extension of visit windows to 14–18 weeks to allow greater flexibility for participants who are 
unwell/isolating, (ii) provision for remote visits with sample collection outside the usual research setting, (iii) ensuring 
participants remained on study therapy when only a remote visit is possible, by allowing an additional ‘continuation’ 
bottle of the same IMP to be issued, or when no other option, transfer to the next IMP without collection of blood 
samples.
DPP4, dipeptidyl peptidase‐4; HbA1c, glycated haemoglobin; IMP, investigational medicinal product; SGLT2, sodium- glucose co- transporter-2.
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metformin alone or metformin and a sulfonylurea with 
HbA1c>58 mmol/mol (>7.5%) and ≤110 mmol/mol 
(≤12.2%). Each participant will attend one screening 
and, if eligible, five research visits over a 12- month period 
(50–60 weeks max/min visit windows). They will receive 
the three blinded second- line and third- line oral therapies 
in random order for 16–18 weeks each, with no washout 
period between therapies. Participant feedback from pilot 
studies found repeated washout periods increased rates of 
withdrawal due to poorly tolerated hyperglycaemia. Once 
stopped, none of the three glucose- lowering agents used 
in this study have a continuing glucose- lowering effect 
beyond 4 weeks (all three drugs have half- lives between 
7 and 14 hours so their effects should be negligible after 
a week)17–19 and HbA1c measurement reflects glycaemia 
over the preceding 8 weeks to 12 weeks period. HbA1c 
measurements taken after 16 weeks will therefore allow a 
4- week ‘wash- in’ period and effectively reflect response to 
each treatment period.
Participants will each act as their own control, and on 
completion of all three treatments will be asked to rank 
the treatments taken in order of preference. Eligible 
participants will be recruited at 20–25 UK sites; the trial 
is sponsored by the Royal Devon and Exeter National 
Health Service (NHS) Foundation Trust and hosted at 
the National Institute for Health Research Exeter Clin-
ical Research Facility. A full list of recruiting sites will be 
available via the ISRCTN registration.
Eligibility criteria
All potential participants will undergo a formal screening 
visit to assess and confirm eligibility as listed in table 1.
Outcome measures
In line with WHO guidelines, response to therapy will 
be assessed by measurement of HbA1c.
20 The primary 
outcome is the HbA1c value achieved after each 16- week 
treatment period. Should a participant be unable to 
complete a full 16- week treatment period, HbA1c will be 
measured and included in the main analysis if the partici-
pant has taken the study drug for at least 12 weeks.
Secondary outcomes will be participant- reported pref-
erence between the three treatments, tolerability of the 
three treatments and prevalence of side effects. In addi-
tion, we will explore sex differences in response to the 
three drugs.
Participant willingness to continue a drug long- term will 
be recorded at the end of each treatment arm. Treatment 
preference, taken as a ranking of the three study drugs 
will be recorded at study completion. To inform this deci-
sion, in addition to their experience on each drug, clinical 
information including HbA1c measurements and weight 
change will be fed- back to each participant. Frequency 
and severity of side effects will be recorded throughout 
the study alongside the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ) to allow a formal validated assess-
ment of participant satisfaction.
HbA1c assessment during the study will be performed in 
local NHS laboratories to ensure results are available for 
screening, and to inform final patient preference. Central 
laboratory analysis will be undertaken at the Exeter Clin-
ical Laboratory at the Royal Devon and Exeter NHS Foun-
dation Trust for all other non- safety sample analysis. All 
analyses are routine biochemistry tests available in the 
NHS test repertoire. All assays are CE marked, fully vali-
dated and accredited by the UK Accreditation Service.
Sample size
Primary outcome is HbA1c at the end of each treatment period
This trial aims to test whether participants in a partic-
ular strata (S) respond differently to drug A and drug B 
compared with patients not in the strata (N). The primary 
outcome is the HbA1c measurement after 4 months of 
each drug (table 2).
The null hypothesis is that the difference in achieved 
HbA1c for the two drugs will be similar for the two groups 
of participants (ie, HbA1cSA−HbA1cSB=HbA1cNA−HbA1cNB 
in table 2).
In a crossover trial of metformin vs repaglinide the SD 
of change in HbA1c on the two different therapies was 
8.7 mmol/mol.21 Analysis of CPRD showed obese patients 
respond better to thiazolidinediones (TZDs) and non- 
obese patients respond better to DPP4is, with an overall 
difference in response between strata of 3.1 mmol/mol 
(equivalent to 0.36SDs). Similarly, higher eGFR >90 mL/
min/1.73 m² is associated with a better HbA1c response 
to SGLT2i, while patients with an eGFR 60–90 mL/
min/1.73 m² had a lower response to the SGLT2i and 
higher response to DPP4i with an overall difference in 
response between strata of 3.0 mmol/mol (equivalent to 
0.35SDs) (Janssen, personal communication, 2014).
Using 90% power, alpha=0.05, to detect a difference of 
0.35SDs we require 172 participants in each stratum, 344 
in total. To allow for the possibility of unequal numbers in 
each stratum, the sample size has been increased to 358, 
assuming a 60:40 split (T2DM population CPRD 52:48 
for both strata); a conservative withdrawal rate of 15% 
increases the study sample size to 422. To allow for partic-
ipants excluded from primary analysis due to fewer than 
12 weeks on one or more study drugs (estimated at 19%), 
we will increase the total sample size for the study to 520.
Investigational medicinal product
Trial interventions were chosen in line with UK NICE 
(National Institute for Health and Care Excellence) 
guidelines for first and second intensification of drug 
treatment in patients with T2DM.2 The three drugs will 
be provided to participants in a blinded format and 
randomised order at the starting dose indicated in the 
British National Formulary; sitagliptin 100 mg, canagli-
flozin 100 mg, pioglitazone 30 mg.
Investigational medicinal products (IMPs) will be 
supplied directly to recruiting site pharmacies by Tayside 
Pharmaceuticals, Dundee, UK. Tablets will be over- 
encapsulated in a hard gelatin capsule so that the IMPs 
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are near identical in size and colour, and packed into 
bottles and distributed to each recruitment site (see 
the Randomisation, allocation and blinding section for 
further details).
Participants will be instructed to take one capsule, once 
daily, alongside their existing diabetes treatment and usual 
medications. They will be given a Drug Information Sheet 
in place of a standard summary of product characteristics 
stating the expected side effects of all three treatments. 
To allow feasible visit windows and prevent participants 
running out of IMP, each IMP bottle will contain 126 
capsules, the equivalent of 18 weeks’ medication.
Where a participant is unable to tolerate a therapy, 
they will move to the next IMP in their randomised 
order, providing they remain clinically safe to continue 
in the study. Dose modification, reduction or delay will 
not be permitted due to the blinded nature of the trial. 
Participants will be asked to return the IMP bottle and 
all unused capsules; research staff will perform a capsule 
count for adherence and accountability purposes.
Randomisation, allocation and blinding
The study has six treatment sequence permutations: 
ABC, ACB, BAC, BCA, CAB and CBA; participants will 
be randomly allocated to one of the six sequences when 
confirmed as eligible in the study database. The study is 
double- blind and all clinical, participant and laboratory 
assessments will be made prior to database lock, final 
analysis and unblinding of the drug order.
A block randomisation list (block size 12) will be 
created using Statsdirect by the Trial Statistician and the 
randomisation seed recorded. The randomisation list will 
be provided to the study database team who will randomly 
allocate blocks of 12 to each of the recruitment sites (to 
ensure balance between the six treatment orders at each 
site), with the allocation remaining blinded to the rest of 
the study team. The IMP supplier will provide each site 
with blocks of 12 drugs (four of each of the three study 
drugs) with the 12 bottle IDs labelled in random order to 
avoid the drug type being easily identifiable. The bottle 
IDs and contents assigned to each recruitment site will be 
recorded in the study database and accessible only to the 
database team.
To ensure allocation concealment, randomisation 
will be centralised via the study database. Eligibility will 
be confirmed by research teams and the participant 
randomised to a blinded treatment order, allocated by 
the study database. Prior to research visits one, two and 
three, the database will allocate the next available IMP 
bottle of the correct drug type held at that site, according 
to this treatment order. Study prescriptions detailing the 
allocated bottle ID will be processed and dispensed by the 
site clinical trials pharmacy.
Participants will not be recruited against specific strata; 
BMI and eGFR defined stratum will be monitored as 
recruitment and randomisation progresses. Data on 
the distribution will be provided to the Data Moni-
toring Committee (DMC) and if enrolment is unevenly 
distributed to an extent that the study hypotheses cannot 
be robustly tested, the relevant stratum may be ‘switched 
off’ by the data programmer to prevent further randomi-
sation into the relevant strata.
Participants who withdraw before randomisation will be 
replaced. However, once randomised, their data will be 
included in analysis. To maintain data quality and trial 
integrity, unblinding via code breaks will occur only in 
exceptional circumstances where knowledge of the IMP 
is deemed essential for the correct clinical management 
of the participant, a medical emergency where someone 
other than the participant has taken the IMP, or where 
this information is needed to establish expectedness 
of a potential Suspected Unexpected Serious Adverse 
Reaction. The emergency code break table is available 
electronically on the study database requiring multiple 
confirmation steps to avoid accidental unblinding, and 
on paper in the central coordinating centre. In the event 
a code break is required this will be done by a member of 
staff independent of the main trial team. A study involve-
ment card with study ID, IMP details, and contact infor-
mation for local and central emergency unblinding will 
be provided to all participants.
Study visits and procedures
Figure 2 illustrates the schedule of assessments.
Identification and recruitment
Potential participants will be identified through primary 
and secondary care, research databases and direct clini-
cian referral, provided with an information sheet, and 
invited to attend a screening visit. Following informed 
consent (online supplemental appendix 2) by trained and 
delegated research staff, clinical characteristics (height, 
weight, waist and hip circumference), medical history, 
concomitant medication details and non- fasting blood 
samples will be collected to confirm eligibility. Eligible 
participants will be randomised into the trial, assigned a 
unique study ID and allocated a drug order.
Baseline visit
Within 2 weeks of screening, participants will attend a 
fasting baseline research visit. Baseline physiological data 
will be collected, along with self- reported compliance 
to existing diabetes medication. Participant’s personal 
priorities in choosing between treatment options and 
experience of side effects on current treatment will also 
be recorded. Participants will have underlying patho-
physiology assessed in a 2- hour mixed- meal tolerance 
test using a standard meal drink (Fortisip). The meal test 
will be undertaken using 250 mL of Nutricia Fortisip or 
160 mL of Nutricia Fortisip Compact. Equivalent prod-
ucts may be used where Fortisip cannot be tolerated. 
Blood and urine samples will be collected for analysis 
and future biomarker discovery at baseline, and then at 
30 min intervals (0, 30, 60, 90 and 120 min) following the 
meal drink. Participants at the central Exeter site will also 
be invited to provide a self- collected genital swab sample 
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to identify development of subclinical colonisation of 
candida or bacteria.
Subsequent research visits will take place after 16–18 
weeks of study treatment. However, patients will be 
offered the opportunity to stop a treatment early and 
move onto the next treatment period if they are unable 
to tolerate the therapy. Visits will repeat the baseline 
physiological measurements with samples collected at a 
single time point. Participants will provide fasting blood 
samples for immediate measurement of HbA1c, and subse-
quent assessment to include fasting glucose, c- peptide, 
insulin, glycosylated albumin, creatinine, lipid profile 
and drug levels. Weight, blood pressure, adherence and 
data about patient experience will also be collected, 
including perceived side effects, preparedness to remain 
on the drug long- term and health- related quality of life. 
Where collected at baseline, subsequent genital swabs will 
be repeated at study visits two to four.
Case report forms will be completed at recruiting 
centres and securely transferred to the central team via 
nhs. net email. OpenText TeleForm will be used for data 
capture and transfer to the study database. Identifiable 
data will be securely stored at recruiting centres, research 
data transferred to Exeter will be accessed only by dele-
gated members of the research team.
Questionnaires: participant preference
On completion of the third study drug, participants will 
be provided with a summary of their previous assessments 
of each therapy. At a final study visit, participants will first 
rank the study drugs based solely on their own experi-
ence on treatment. HbA1c and weight data for each drug 
period will then be provided by the research team, and 
a repeat ranking recorded. This summary assessment 
was developed with the TriMaster Patient Involvement 
Group and the Peninsula Research Bank Lay Committee 
members. Endpoints of willingness to remain on study 
drug long- term, and impact on daily life were identified 
as the best representations to capture participant prefer-
ence for the study.
A final version of drug preference and clinical data will 
be provided to the participant and their clinician. This 
document, provided directly by the Exeter CTU team to 
ensure research teams remain blinded throughout, will 
contain details of the unblinded study drugs A, B and C to 
inform future treatment choices. All study procedures will 
occur within the 50–60- week trial period but permission 
will be requested to contact participants after primary 
analysis is complete to assess future treatment choice.
Participants will also complete the DTSQ at baseline 
and the change version (DTSQc) after each treatment 
period to collect validated satisfaction scores.
Statistical analysis
Analyses and reporting will follow Consolidated Stan-
dards of Reporting Trials guidance for randomised cross-
over trials.22 This study is not designed to test drug efficacy 
but the effectiveness of stratification. Therefore, only 
patients completing at least 12 weeks on therapy (suffi-
cient to allow HbA1c to reflect glycaemia control on the 
drug) will be included in primary analysis. In addition, 
we will perform a secondary analysis of tolerability exam-
ining whether the proportion of participants completing 
at least 12 weeks differs for each drug, both within strata 
and overall.
Prior to main analysis, we will determine whether there 
is any evidence of carryover or period effects. Any carry-
over effect identified will be reported but not adjusted 
for in subsequent analysis. Period effects will be reported 
and adjusted for. We do not anticipate treatment effect 
carryover and have designed the study to limit potential 
carryover (as far as possible). Any period effect in the 
maximum 8 months between on treatment HbA1cs is 
likely to be minimal as mean progression is 1.0 mmol/
mol/year (E Pearson, personal communication, data 
from GoDARTs population data).
There will be two primary analyses, one for each of the 
study hypotheses. For each hypothesis the primary anal-
ysis will be to assess whether the difference in achieved 
HbA1c measurements for the two drugs is similar for the 
two groups of participants. The two hypotheses will be 
tested separately using linear mixed effects models to 
compare the strata on the two drugs of interest, with a 
random effects term for the participant. The key contrast 
of interest is the drug*strata interaction, where the strata 
is either obesity group or eGFR group. To determine 
whether there is a difference between drug classes in 
terms of the overall achieved HbA1c after 4 months on 
each of the drugs, we will fit an additional model. Drug 
will be a factor and coded as a dummy variable as the 
comparison will be across three rather than two drug 
classes. Least square means will be extracted for the three 
drugs. Similar analysis will be carried out with weight after 
4 months as the outcome.
In addition, we will examine the distribution of side 
effects reported across each of the three drugs. However, 
given the total numbers reporting each individual side 
effect will likely be small, we anticipate this will largely 
be descriptive, examining proportion of side effects 
observed with each drug.
For analysis of patient preference, we will only analyse 
the dataset where the participants have tried all three 
drugs. The mean rank for each drug will be calculated 
and tested against the null hypothesis that there is not a 
preferred drug and therefore the expected value of the 
rank for a given drug will be two. Further investigation of 
patient preference will be exploratory.
Reasons for missing data will be documented and the 
baseline characteristics of those with and without missing 
data compared.
Monitoring
Due to the nature of standard diabetes treatments, it is 
expected that participants will experience some mild 
adverse events or reactions. These will be recorded at 
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research visits and reported on a study- wide basis to the 
sponsor and DMC at regular intervals.
Serious adverse reactions where the IMP is assessed 
as having possible, probable or definite causality will be 
unblinded to enable full evaluation of expectedness in 
the context of the relevant safety profile. Independent 
auditing of the trial will be arranged by the sponsor, in 
addition to sponsor review.
Oversight committees
The study will be run by a Trial Management Group with 
oversight from an independent Trial Steering Committee 
and DMC. These committees comprise independent 
experts in diabetes and statistical methodology and 
patient representatives and will meet regularly to monitor 
the scientific integrity and safety of the trial and provide 
independent advice. To ensure the safety of participants, 
the DMC will review unblinded safety data.
ETHICS AND DISSEMINATION
This study has been reviewed and received ethics approval 
from the NHS Health Research Authority (HRA) Research 
Ethics Committee South Central—Oxford A, study 16/
SC/0147. The clinical trial application was reviewed and 
approved by the UK Medicines and Healthcare products 
Regulatory Agency (MHRA) under EudraCT reference. 
All substantial and non- substantial amendments have 
received approval from HRA, REC and MHRA before 
implementation. The protocol has been registered with 
ClinicalTrials. gov and ISRCTN (trial registration dataset 
in online supplemental appendix 3).
All participants will be provided verbal and written 
information about the study prior to providing written 
informed consent and will be free to withdrawn at any time 
without affecting current or future clinical treatment.
Changes to protocol
The study was first registered with  Clinicaltrials. gov on 
12 January 2016 and ISRCTN on 02 November 2016. 
Approved protocol amendments are in table 3.
Dissemination
Data and results related to protocol- derived outcomes will 
be published in peer- reviewed journals by the chief inves-
tigator on behalf of the MASTERMIND consortium and 
presented at scientific meetings. Anonymous trial data 
will be shared within the MASTERMIND consortium and 
after publication of results, data will be securely depos-
ited in Exeter’s institutional repository and made avail-
able on request via the consortium’s data access group. A 
lay summary will be provided to all study participants and 
made available on the study website, and public registries.
Patient and public involvement
Patients were involved in the design and conduct of 
this study. Following pilot studies, the TriMaster Patient 
Involvement Group provided feasibility feedback on 
the study design and the outcome measures used to 
record patient preference and experience of the study 
drugs. This group and the Peninsula Research Bank Lay 
Committee members assisted in the design of patient- 
facing documents, including consent forms, study and 
drug information sheets and data collection forms to 
assess patient preference.
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Reporting checklist for protocol of a clinical trial – 
TriMaster  
Based on the SPIRIT guidelines: Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, 
Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, 
Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining 
standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207 
  Reporting Item 
Page 
Number 
Administrative information  
Title #1 Descriptive title identifying the study design, population, 
interventions, and, if applicable, trial acronym 
1 
Trial registration #2a Trial identifier and registry name. If not yet registered, 
name of intended registry 
2 
Trial registration: 
data set 
#2b All items from the World Health Organization Trial 
Registration Data Set 
Appendix 3 
Protocol version #3 Date and version identifier 16 
Funding #4 Sources and types of financial, material, and other 
support 
15 
Roles and 
responsibilities: 
contributorship 
#5a Names, affiliations, and roles of protocol contributors 1 & 14 
Roles and 
responsibilities: 
sponsor contact 
information 
#5b Name and contact information for the trial sponsor Appendix 3 
Roles and 
responsibilities: 
sponsor and funder 
#5c Role of study sponsor and funders, if any, in study 
design; collection, management, analysis, and 
interpretation of data; writing of the report; and the 
decision to submit the report for publication, including 
whether they will have ultimate authority over any of 
these activities 
15 
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Roles and 
responsibilities: 
committees 
#5d Composition, roles, and responsibilities of the 
coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and 
other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee) 
14-15  
Introduction    
Background and 
rationale 
#6a Description of research question and justification for 
undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits 
and harms for each intervention 
2 
Background and 
rationale: choice of 
comparators 
#6b Explanation for choice of comparators 3 
Objectives #7 Specific objectives or hypotheses 4 
Trial design #8 Description of trial design including type of trial (eg, 
parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, 
equivalence, non-inferiority, exploratory) 
5 
 
Methods: Participants, interventions, and outcomes 
 
Study setting #9 Description of study settings (eg, community clinic, 
academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can 
be obtained 
5 
Eligibility criteria #10 Inclusion and exclusion criteria for participants. If 
applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, 
surgeons, psychotherapists) 
6 
Interventions: 
description 
#11a Interventions for each group with sufficient detail to 
allow replication, including how and when they will be 
administered 
9 
Interventions: 
modifications 
#11b Criteria for discontinuing or modifying allocated 
interventions for a given trial participant (eg, drug dose 
9 
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change in response to harms, participant request, or 
improving / worsening disease) 
Interventions: 
adherance 
#11c Strategies to improve adherence to intervention 
protocols, and any procedures for monitoring adherence 
(eg, drug tablet return; laboratory tests) 
10  
Interventions: 
concomitant care 
#11d Relevant concomitant care and interventions that are 
permitted or prohibited during the trial 
7 
Outcomes #12 Primary, secondary, and other outcomes, including the 
specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, 
final value, time to event), method of aggregation (eg, 
median, proportion), and time point for each outcome. 
Explanation of the clinical relevance of chosen efficacy 
and harm outcomes is strongly recommended 
8 
Participant timeline #13 Time schedule of enrolment, interventions (including 
any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly 
recommended (see Figure) 
Figures 1 
& 2 
Sample size #14 Estimated number of participants needed to achieve 
study objectives and how it was determined, including 
clinical and statistical assumptions supporting any 
sample size calculations 
8 
Recruitment #15 Strategies for achieving adequate participant enrolment 
to reach target sample size 
11 
 
Methods: Assignment of interventions (for controlled trials) 
 
Allocation: sequence 
generation 
#16a Method of generating the allocation sequence (eg, 
computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a 
random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate 
document that is unavailable to those who enrol 
participants or assign interventions 
9 
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Allocation 
concealment 
mechanism 
#16b Mechanism of implementing the allocation sequence 
(eg, central telephone; sequentially numbered, opaque, 
sealed envelopes), describing any steps to conceal the 
sequence until interventions are assigned 
10 
Allocation: 
implementation 
#16c Who will generate the allocation sequence, who will 
enrol participants, and who will assign participants to 
interventions 
10 
Blinding (masking) #17a Who will be blinded after assignment to interventions 
(eg, trial participants, care providers, outcome 
assessors, data analysts), and how 
10 
Blinding (masking): 
emergency 
unblinding 
#17b If blinded, circumstances under which unblinding is 
permissible, and procedure for revealing a participant’s 
allocated intervention during the trial 
10 
 
Methods: Data collection, management, and analysis 
 
Data collection plan #18a Plans for assessment and collection of outcome, 
baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate 
measurements, training of assessors) and a description 
of study instruments (eg, questionnaires, laboratory 
tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, 
if not in the protocol 
Figure 2 & 
pages 7 & 
11 
Data collection plan: 
retention 
#18b Plans to promote participant retention and complete 
follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate 
from intervention protocols 
10 
Data management #19 Plans for data entry, coding, security, and storage, 
including any related processes to promote data quality 
(eg, double data entry; range checks for data values). 
Reference to where details of data management 
procedures can be found, if not in the protocol 
12 
Statistics: outcomes #20a Statistical methods for analysing primary and secondary 
outcomes. Reference to where other details of the 
13 
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statistical analysis plan can be found, if not in the 
protocol 
Statistics: additional 
analyses 
#20b Methods for any additional analyses (eg, subgroup and 
adjusted analyses) 
14 
Statistics: analysis 
population and 
missing data 
#20c Definition of analysis population relating to protocol non-
adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple 
imputation) 
14 
 
Methods: Monitoring 
 
Data monitoring: 
formal committee 
#21a Composition of data monitoring committee (DMC); 
summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and 
competing interests; and reference to where further 
details about its charter can be found, if not in the 
protocol. Alternatively, an explanation of why a DMC is 
not needed 
14  
Data monitoring: 
interim analysis 
#21b Description of any interim analyses and stopping 
guidelines, including who will have access to these 
interim results and make the final decision to terminate 
the trial 
NA 
Harms #22 Plans for collecting, assessing, reporting, and managing 
solicited and spontaneously reported adverse events 
and other unintended effects of trial interventions or trial 
conduct 
14 
Auditing #23 Frequency and procedures for auditing trial conduct, if 
any, and whether the process will be independent from 
investigators and the sponsor 
14 
    
 
Ethics and dissemination 
 
Research ethics 
approval 
#24 Plans for seeking research ethics committee / 
institutional review board (REC / IRB) approval 
2 
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Protocol 
amendments 
#25 Plans for communicating important protocol 
modifications (eg, changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, 
investigators, REC / IRBs, trial participants, trial 
registries, journals, regulators) 
16 
Consent or assent #26a Who will obtain informed consent or assent from 
potential trial participants or authorised surrogates, and 
how (see Item 32) 
11 
Consent or assent: 
ancillary studies 
#26b Additional consent provisions for collection and use of 
participant data and biological specimens in ancillary 
studies, if applicable 
NA 
Confidentiality #27 How personal information about potential and enrolled 
participants will be collected, shared, and maintained in 
order to protect confidentiality before, during, and after 
the trial 
12 
Declaration of 
interests 
#28 Financial and other competing interests for principal 
investigators for the overall trial and each study site 
16 
Data access #29 Statement of who will have access to the final trial 
dataset, and disclosure of contractual agreements that 
limit such access for investigators 
14 
Ancillary and post 
trial care 
#30 Provisions, if any, for ancillary and post-trial care, and 
for compensation to those who suffer harm from trial 
participation 
NA 
Dissemination 
policy: trial results 
#31a Plans for investigators and sponsor to communicate trial 
results to participants, healthcare professionals, the 
public, and other relevant groups (eg, via publication, 
reporting in results databases, or other data sharing 
arrangements), including any publication restrictions 
15 
Dissemination 
policy: authorship 
#31b Authorship eligibility guidelines and any intended use of 
professional writers 
NA 
Dissemination 
policy: reproducible 
research 
#31c Plans, if any, for granting public access to the full 
protocol, participant-level dataset, and statistical code 
15 
Appendices    
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Informed consent 
materials 
#32 Model consent form and other related documentation 
given to participants and authorised surrogates 
Appendix 2 
Biological 
specimens 
#33 Plans for collection, laboratory evaluation, and storage 
of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary 
studies, if applicable 
Figure 2 & 
page 7 
 
The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
BY-ND 3.0. This checklist can be completed online using https://www.goodreports.org/, a tool made 
by the EQUATOR Network in collaboration with Penelope.ai 
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TriMaster Consent Form V3 08.05.2018 IRAS: 183044                                                                                          
Site Logo(s) 
Sponsored by the Royal Devon and 
Exeter NHS Foundation Trust  
 
STUDY NAME:  
TRIMASTER   
 
 
 
CONSENT STATEMENTS 
Please 
circle 
Initials 
I have been given study information leaflet [Version [  ] dated [      ]] and 
supplementary information about the treatments used in this study.  I have had 
the opportunity to ask questions and have had these answered satisfactorily.  
 
YES/NO 
 
I am happy to: 
 attend 6 appointments, having fasted overnight for 4 of these.  
 try 3 different regularly prescribed diabetes treatments for up to 16 weeks 
each. 
 provide information about my diabetes for use in this project.  
 allow the research team to contact my clinicians/GP about my diabetes 
treatment and study participation, and to provide them with clinical results 
relevant to my care. 
 provide blood and urine samples for use by this study. 
 
 
 
YES/NO 
 
I understand that: 
 my participation is voluntary and that I may withdraw at any time without 
my clinical care being affected.  
 individuals from the study team, regulatory authorities or the NHS Trust will 
have access to relevant sections of my medical notes and data collected 
during the study for research, monitoring and audit purposes. 
 
YES/NO 
 
OPTIONAL CONSENT STATEMENTS 
I agree that DNA may be extracted from samples for the purpose of this project  YES/NO  
I am happy to provide self-collected genital swabs (Exeter site only). YES/NO  
I am happy to gift samples and data from the project to the Peninsula Research 
Bank in Exeter to be used for future research. 
YES/NO 
 
I agree that information held by the NHS and in my medical records may be 
used to follow up on my future health status. 
YES/NO 
 
I am happy to be contacted by my local research team about participating in 
other future studies. 
YES/NO 
 
 
Participant Name  Signed  Date 
 
 
   
/      / 
I confirm that I am on the delegation log for the TriMaster study to obtain consent.  In my opinion the 
participant understands what this study involves and has capacity to take part. 
Name of Person Obtaining Consent  Signed  Date 
 
 
   
/      / 
Clinician Confirming Eligibility*   Signed  Date 
 
 
   
/      / 
 
* Eligibility (eligible/non-eligible) confirmed as indicated on the screening CRF  
When completed: 1 for participant; 1 for researcher site file; 1 to be kept in medical notes (front page only)  
DOB  
 
      /      / 19     
 
Screening ID:   Study ID:  
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Please stick consent barcode label below:  
Visit 1 consent barcode Visit 2 consent barcode 
 
Visit 4 consent barcode 
 
Visit 3 consent barcode 
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Data Category Information 
Primary registry and trial identifying number ClinicalTrials.gov NCT02653209 
Date of registration in primary registry 8 January 2016 
Secondary identifying numbers EudraCT 2015-002790-38; ISRCTN12039221; 
Sponsor 1603221; Funder MR/N00633X/1; HRA 
16/SC/0147; IRAS 183044 
Source(s) of monetary or material support Medical Research Council, UK 
Primary sponsor Royal Devon and Exeter NHS Foundation Trust 
Sponsor contact details Alison Kerridge, Assistant R&D Manager;  
Research and Development, 
First Floor, Bowmoor House 
Barrack Road, 
Exeter 
EX2 5DW 
alison.kerridge@nhs.net; 01392 403055 
Contact for public queries Catherine Angwin, Trial Manager; 
NIHR Exeter Clinical Research Facility 
Room 02.15, RILD Building 
Barrack Road 
Exeter 
EX2 5DW 
Rde-tr.DiabetesDrugResponse@nhs.net; 01392 
408180 
Contact for scientific queries Professor Andrew Hattersley FRCP FMedSci 
FRS, Chief Investigator; 
University of Exeter Medical School 
RILD Building 
Barrack Road 
Exeter 
EX2 5DW 
A.T.Hattersley@exeter.ac.uk; 01392 408260 
Public title TriMaster: Study of a DPP4 inhibitor, SGLT2 
Inhibitor and Thiazolidinedione as Third Line 
Therapy in patients with Type 2 Diabetes. 
Scientific title TriMaster: Randomised Double-Blind Crossover 
Study of a DPP4 Inhibitor, SGLT2 Inhibitor and 
Thiazolidinedione as Third Line Therapy in 
Patients With Type 2 Diabetes Who Have 
Suboptimal Glycaemic Control on Dual Therapy 
with Metformin and a Sulphonylurea 
Countries of recruitment United Kingdom 
Health condition(s) or problem(s) studied Type 2 Diabetes 
Intervention(s) Drug: Sitagliptin (2x50mg as over-encapsulated 
hard shell to be taken orally, once a day); Drug: 
Canagliflozin (100mg as over-encapsulated hard 
shell to be taken orally, once a day); Drug: 
Pioglitazone (30mg as over-encapsulated hard 
shell to be taken orally, once a day) 
All participants receive all 3 interventional 
treatments for 16 weeks each in random order 
according to one of 6 possible treatment order 
(ABC, ACA, BAC, BCA, CAB, CBA) with no 
washout period 
Key inclusion and exclusion criteria Ages eligible for study: 30 – 80 years (inclusive); 
Sexes eligible for study: both; Accepts healthy 
volunteers: no 
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Inclusion Criteria: Clinical diagnosis of Type 2 
diabetes, Age ≥30 and ≤80, currently treated 
with two classes of oral glucose-lowering 
therapy that do not include a DPP4-inhibitor, a 
SGLT2 inhibitor or a thiazolidinedione, diabetes 
duration  ≥12 months, no change in diabetes 
treatment (new treatments or dose change) 
within previous 3 months, HbA1c 
>58mmol/mol (7.5%) and ≤110mmol/mol 
(12.2%) – confirmed at screening visit, eGFR 
≥60mls/min/1.73m2 – confirmed at screening 
visit, able and willing to give informed consent 
Exclusion Criteria: Changes in glucose-lowering 
therapy or dose within last 3 months, HbA1c 
≤58mmol/mol (7.5%) or >110mmol/mol 
(12.2%), eGFR <60mls/min/1.73m2, diabetes 
duration <12 months, ALT >2.5 x upper limit of 
the assay normal range or known liver disease, 
specifically >30µmol/L that is associated with 
other evidence of liver failure, insulin treated 
within the last 12 months, limb ischaemia 
shown by absence of both pulses in one or both 
feet, currently treated with corticosteroids, 
currently treated with rifampicin, gemfibrozil, 
phenytoin and carbamazepine, active infection 
(requiring antibiotics at present), foot ulcer 
requiring antibiotics within previous three 
months, recent (within 3 months) significant 
surgery or planned surgery (excluding minor 
procedures), acute cardiovascular episode 
(angina, myocardial infarction, stroke, transient 
ischemic episode) occurring within the previous 
3 months, history of heart failure, current use 
of loop diuretic therapy (Furosemide or 
Bumetanide), history of bladder carcinoma, 
current/ongoing investigation for macroscopic 
haematuria, history of diabetic ketoacidosis, 
history of pancreatitis, pregnant, breastfeeding 
or planning a pregnancy over the study period, 
concurrent participation on another CTIMP 
(where IMP is currently being taken or without 
sufficient washout period), unable or unwilling 
to give informed consent 
Study type Interventional 
Allocation: Randomised; Intervention model: 
Crossover assignment; Masking: Double 
(Participant, Investigator) 
Primary Purpose: Treatment 
Phase 4 
Date of first enrolment 1 November 2016 
Target sample size 525 (reduced from 600) 
Recruitment status Active, not recruiting 
Primary outcome(s) On treatment HbA1c in obese patients 
(BMI>30kgm-2) compared to non-obese 
patients (BMI<30kgm-2), (time frame: 16 
weeks); On treatment HbA1c in patients with 
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an eGFR<90mls/min/1.73m2 compared to 
patients with an eGFR>90mls/min/1.73m2, 
(time frame: 16 weeks) 
Key secondary outcomes Patient preference [Time frame: 48-54 weeks 
(3x16 weeks of therapy)]; Prevalence of side 
effects [Time frame: 48-54 weeks (3x16 weeks 
of therapy)]; HbA1c on therapy against 
predefined test of gender heterogeneity (Time 
frame: 16 weeks) 
Ethics Review Status: Approved 
Date of Approval: 9 May 2016 
South Central – Oxford A Research Ethics 
Committee 
Nrescommittee.southcentral-oxforda@nhs.net 
Completion Date January 2021 
Summary Results N/A as study has not completed yet 
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